Dose modification with CYENDIV® (nintedanib) allows for the management of GI and liver side effects without compromising efficacy. For those patients who did not tolerate the 150mg dose, temporary dose reduction to 100mg twice daily was demonstrated to be beneficial.1
- Richeldi L., et al. Effect of dose reductions, treatment interruptions and dose intensity on decline in lung function with nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from the INPULSIS® trials (Poster). PFF Summit 2015;Washington DC, US.
- Corte T., et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res 2015;16. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581488/. Accessed January 11, 2016.